Bristol Meyers Squibb CEO to step down
Bristol Meyers Squibb could become another contender for ONCY because of ONCY's alignment with the Celgene immuno-oncology assets. BMS is a US$143 Billion company.
https://www.bms.com/researchers-and-partners/in-the-pipeline.html
https://endpts.com/bristol-myers-ceo-giovanni-caforio-to-step-down-in-november/